Dr. Lappin is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
801 N Tustin Ave
Suite 700
Santa Ana, CA 92705Phone+1 714-541-4185Fax+1 714-541-3465
Education & Training
- Baylor College of Medicine/Cullen Eye InstituteResidency, Ophthalmology, 1971 - 1974
- Los Angeles County-Harbor-UCLA Medical CenterResidency, Orthopaedic Surgery, 1968 - 1969
- University of Southern California/LACUSC Medical CenterInternship, Transitional Year, 1967 - 1968
- University of Tennessee Health Science Center College of MedicineClass of 1967
Certifications & Licensure
- CA State Medical License 1968 - 2025
- FL State Medical License 1973 - 2025
- TX State Medical License 1972 - 1992
- TN State Medical License 1967 - 1973
- American Board of Ophthalmology Ophthalmology
Awards, Honors, & Recognition
- Fellow (FACS) American College of Surgeons
- Fellow (FAAO) American Academy of Ophthalmology
Publications & Presentations
PubMed
- 53 citationsPeptide Immunization Indicates that CD8+ T Cells are the Dominant Effector Cells in Trinitrophenyl-Specific Contact HypersensitivityStefan F. Martin, Michael B. Lappin, Jochen Kohler, Virginie Delattre, Cornelia Leicht
The Journal of Investigative Dermatology. 2000-08-01 - 3 citationsThe role of cis-urocanic acid in UVB-induced immunosuppression.Michael B. Lappin, Ali A. El-Ghorr, Ian Kimber, Mary Norval
Advances in Experimental Medicine and Biology. 1995-01-01 - 55 citationsThe role of dendritic cells in cutaneous immunityMichael B. Lappin, Ian Kimber, Mary Norval
Archives of Dermatological Research. 1996-03-01
Press Mentions
- Bears, Baboons, Tigers Are Getting COVID Vaccines at Zoos Across the U.S.August 20th, 2021
- The Bioequivalence of Two Peficitinib Formulations, and the Effect of Food on the Pharmacokinetics of Peficitinib: Two‐Way Crossover Studies of a Single Dose of 150 Mg Peficitinib in Healthy VolunteersJuly 3rd, 2020
- What’s Causing Severe Respiratory Illnesses in Dogs?February 15th, 2024
Professional Memberships
- Fellow
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: